Sino Biopharmaceutical Limited

SZSC:1177 Stock Report

Market Cap: HK$59.2b

Sino Biopharmaceutical Past Earnings Performance

Past criteria checks 4/6

Sino Biopharmaceutical's earnings have been declining at an average annual rate of -13.6%, while the Pharmaceuticals industry saw earnings growing at 5% annually. Revenues have been growing at an average rate of 2.9% per year. Sino Biopharmaceutical's return on equity is 12%, and it has net margins of 7.7%.

Key information

-13.6%

Earnings growth rate

-13.4%

EPS growth rate

Pharmaceuticals Industry Growth5.6%
Revenue growth rate2.9%
Return on equity12.0%
Net Margin7.7%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Sino Biopharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

SZSC:1177 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2427,7902,14211,6890
31 Mar 2426,9951,99511,3780
31 Dec 2326,1991,84711,0670
30 Jun 2325,1161,25411,0010
31 Mar 2325,5711,65611,3550
31 Dec 2226,0262,05911,7090
30 Sep 2228,2415,29612,7050
30 Jun 2227,7018,04912,8460
31 Mar 2227,21513,65512,6690
31 Dec 2126,86114,60812,7040
30 Sep 2126,12912,46512,7180
30 Jun 2125,35310,01112,7540
31 Mar 2124,6683,80912,1980
31 Dec 2023,6472,77111,6290
30 Sep 2023,0392,30211,2540
30 Jun 2024,3542,55811,4900
31 Mar 2024,2482,78111,7620
31 Dec 1924,2342,76211,7970
30 Sep 1924,4799,10112,5440
30 Jun 1923,6919,12511,8010
31 Mar 1922,4449,13211,0360
31 Dec 1820,8899,04610,2680
30 Sep 1819,1032,5678,7990
30 Jun 1817,0622,4367,9210
31 Mar 1815,6092,3637,3340
31 Dec 1714,8192,1716,9050
30 Sep 1714,4912,1156,6800
30 Jun 1714,2581,8626,6680
31 Mar 1713,8991,7896,5250
31 Dec 1613,5431,6376,4930
30 Sep 1613,2711,6746,3440
30 Jun 1612,8581,6046,2720
31 Mar 1612,5071,5756,0840
31 Dec 1512,1891,4905,9740
30 Sep 1512,0301,4325,9940
30 Jun 1511,1241,4475,4830
31 Mar 1510,5521,2635,2520
31 Dec 149,9001,2104,9330
30 Sep 149,2051,0744,4570
30 Jun 148,8769514,3660
31 Mar 148,4348864,2870
31 Dec 137,7318093,9450

Quality Earnings: 1177 has high quality earnings.

Growing Profit Margin: 1177's current net profit margins (7.7%) are higher than last year (5%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 1177's earnings have declined by 13.6% per year over the past 5 years.

Accelerating Growth: 1177's earnings growth over the past year (70.9%) exceeds its 5-year average (-13.6% per year).

Earnings vs Industry: 1177 earnings growth over the past year (70.9%) exceeded the Pharmaceuticals industry 6.1%.

Return on Equity

High ROE: 1177's Return on Equity (12%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y